Janney Montgomery Scott LLC Invests $3.23 Million in Insulet Co. (PODD)
Janney Montgomery Scott LLC acquired a new stake in shares of Insulet Co. (NASDAQ:PODD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 58,628 shares of the medical instruments supplier’s stock, valued at approximately $3,229,000. Janney Montgomery Scott LLC owned approximately 0.10% of Insulet as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rosenblum Silverman Sutton S F Inc. CA acquired a new stake in shares of Insulet during the 2nd quarter valued at $2,122,000. Geneva Advisors LLC boosted its holdings in shares of Insulet by 2.3% during the 2nd quarter. Geneva Advisors LLC now owns 22,215 shares of the medical instruments supplier’s stock valued at $1,140,000 after acquiring an additional 504 shares in the last quarter. FMR LLC boosted its holdings in shares of Insulet by 0.5% during the 2nd quarter. FMR LLC now owns 8,687,487 shares of the medical instruments supplier’s stock valued at $445,755,000 after acquiring an additional 39,836 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Insulet by 3.2% during the 2nd quarter. Northern Trust Corp now owns 777,986 shares of the medical instruments supplier’s stock valued at $39,919,000 after acquiring an additional 24,188 shares in the last quarter. Finally, Paulson & CO. Inc. acquired a new stake in shares of Insulet during the 2nd quarter valued at $1,283,000.
In related news, Director James C. Mullen bought 2,500 shares of the business’s stock in a transaction on Monday, November 13th. The shares were purchased at an average cost of $67.45 per share, with a total value of $168,625.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.90% of the stock is currently owned by insiders.
Insulet Co. (NASDAQ:PODD) opened at $68.45 on Friday. Insulet Co. has a twelve month low of $36.80 and a twelve month high of $72.99. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65.
Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million for the quarter, compared to the consensus estimate of $114.02 million. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.05) EPS. analysts predict that Insulet Co. will post -0.42 earnings per share for the current year.
PODD has been the topic of several recent research reports. Jefferies Group raised their price objective on Insulet from $58.00 to $67.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Zacks Investment Research downgraded Insulet from a “buy” rating to a “hold” rating in a report on Saturday, November 11th. Wedbush reissued a “buy” rating and set a $65.00 price objective (up previously from $60.00) on shares of Insulet in a report on Tuesday, October 10th. Canaccord Genuity reissued a “hold” rating and set a $50.00 price objective on shares of Insulet in a report on Wednesday, September 27th. Finally, BidaskClub downgraded Insulet from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Eight investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Insulet presently has a consensus rating of “Buy” and an average price target of $61.29.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with Analyst Ratings Network's FREE daily email newsletter.